Mineralys Therapeutics, Inc.
MLYS · XNASCIK 1933414fmd_1FXHRWJ92RQ5RNCGBYY9JP4BJJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Sep 30, 2026, 19 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Research and development | 26 | 70 | 169 | 132 |
| Total operating expenses | 31 | 85 | 192 | 171 |
| Operating income | (31) | (85) | (192) | (171) |
| Other non-operating income (expense) | 2 | 13 | 15 | 16 |
| Income tax expense | – | – | – | 0 |
| Net income | (30) | (72) | (178) | (155) |